In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: updated subgroup analysis from the fully accrued US MM-6 study
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2023)
关键词
parenteral bortezomib,multiple myeloma,oral ixazomib,frailty status,in-class
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要